ENTITY

GI Cell (GICELL KS)

1
Analysis
Health CareSouth Korea
The company develops immune cell-based therapeutics and vaccines for the treatment of cancer, inflammatory disorders, and infectious diseases. Its platform technology optimizes ancillary proteins for target immune cells and engineers multi-valent sub-unit vaccines, providing medical practitioners with specialized solutions for complex disease management.
more
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
x